- Home
- AARD vs SERA Comparison
AARD vs SERA Comparison
Compare AARD & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | SERA |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 75.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AARD | SERA |
|---|---|---|
| Price | $6.09 | $1.67 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $15.29 | N/A |
| AVG Volume (30 Days) | ★ 127.6K | 23.9K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $3.35 | $1.37 |
| 52 Week High | $17.94 | $4.09 |
Technical Indicators
Market Signals| Indicator | AARD | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 34.37 |
| Support Level | $4.81 | N/A |
| Resistance Level | $11.37 | $2.41 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 90.70 | 13.28 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.